# NCT04958811 (NCT04958811)

> Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

No report yet. It can be ordered.

- Drugs tested: tiragolumab plus atezolizumab plus bevacizumab
- Indication: previously-treated advanced non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04958811
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Georgetown University
- Conditions: Non-squamous Non-small-cell Lung Cancer
- Interventions: Tiragolumab; Atezolizumab; Bevacizumab
- Enrollment: 29
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on NCT04958811 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04958811